CLIENTRON-CORP.
15.10.2019 15:02:04 CEST | Business Wire | Press release
Clientron Corp., a leading global provider of Thin Client, POS and embedded systems, introduces the brand new all-in-one Thin Client TC238 that features a 23.8” display with fanless and ultra-slim enclosure, and system designed with the concept of Intel® Smart Display Module (Intel® SDM) for optimized display computing. The TC238 AiO thin client runs on client-server architecture and can be implemented with major existing VDI protocols to deliver the best user computing experience for virtual desktop solutions.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191015005364/en/
Easy deployment and maintenance to optimize user experience
The TC238 AiO thin client designed with Intel® Smart Display Module (SDM-Large) featuring open pluggable, flexible integration, easy deployment and maintenance design to reduce total cost of ownership.
Energy-efficient and high performance for End user computing
Powered by high performance and power efficient Intel® Braswell x5-E8000 quad core processors, the TC238 AiO thin client supports DDR3L-1600 memory, storage options including mSATA SSD and on-board eMMC storages as manufacturing optional. The I/O connectors include two USB3.2 Gen 1 ports, two USB 2.0 ports, one DisplayPort, one DVI, audio ports as well as networking ability with a M.2 interface for WiFi and Bluetooth functionality.
High-density viewing and space-saving benefits
Featuring ultra-slim enclosure, the TC238 AiO thin client supports 23.8” full HD display and anti-glare panel for comfortable reading. Powered by one wire, it offers streamline and space-saving benefits for operations. In additions, it supports 4K display output to give users a rich, high-density viewing on external monitor.
Enhanced System Security & Virtual Desktop solutions
The TC238 thin client supports Trusted Platform Module (TPM) by manufacturing optional for secure data protection. Moreover, it supports all mainstream virtual desktop protocols including Microsoft RDP/ RemoteFX/WVD, Citrix HDX, and VMware Horizon View to ensure high availability and seamless communication with other applications.
The AiO TC238 thin client features highlight:
- Power-efficient Intel® Braswell x5-E8000 Quad Core Processor with fanless design
- Ultra-slim enclosure with open pluggable Intel® Smart Display Module (SDM-Large)
- Stylish 23.8” Full HD display with LED backlight
- Support up to 4K resolution for external display
- Able to rotate screen to upright position with optional stand
- Adjustable display swivel and tilt angle
- Support two USB 3.2 Gen 1, two USB 2.0, Giga LAN
- Support VESA mount for various mounting solutions
- Support Kensington lock
- Optional Wi-Fi module (M.2 2230 E Key Socket)
- Factory option for eMMC and TPM
The Clientron AiO Thin Client TC238 is available now. For more product details, please contact Clientron sales or visit our website www.clientron.com
About Clientron
Clientron is dedicated to be the professional thin client, POS, Automotive Electronics and embedded computing ODM provider for over 15 years. With providing Design, Manufacturing and Service support abilities for embedded computing, Clientron is your best embedded solution partner to empower more efficiency and safety for your e-World. Visit us at www.clientron.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20191015005364/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom